H-VVV^GAVGVGK^-OH

Ref. 3D-PP48026

Informations sur le produit

• Nom: H-VVV^GAVGVGK^-OH

Description

Peptide H-VVV^GAVGVGK^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-VVV^GAVGVGK^-OH include the following: Abstract C004: TCRs directed to mutant KRAS display distinct antigen recognition motifs and minimal cross-reactivity to non-cognate antigens RB Nadler, A Bear , RH Vonderheide, GP Linette - Cancer Research, 2022 - AACRhttps://aacrjournals.org/cancerres/article/82/22_Supplement/C004/710393 Identification of T-cell receptors targeting KRAS-mutated human tumors QJ Wang, Z Yu, K Griffith, K Hanada, NP Restifo - Cancer immunology , 2016 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/4/3/204/468486 Mutated RAS: targeting the"Untargetable" with T cells PD Chatani, JC Yang - Clinical Cancer Research, 2020 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/26/3/537/83143 Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy N Levin , BC Paria, NR Vale, R Yossef , FJ Lowery - Clinical Cancer , 2021 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/27/18/5084/671639 Identification and Structural Characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3 MJW Sim , K Hanada, Z Stotz, Z Yu, J Lu, P Brennan - bioRxiv, 2024 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2024.02.01.578367.abstract Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations J Choi, SP Goulding , BP Conn, CD McGann - Cell reports , 2021 - cell.comhttps://www.cell.com/cell-reports-methods/pdf/S2667-2375(21)00139-9.pdf Systematic discovery of Neoepitope-HLA pairs for neoantigens shared among patients and tumor types HR Gurung , AJ Heidersbach, M Darwish - Nature , 2023 - nature.comhttps://www.nature.com/articles/s41587-023-01945-y Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations GP Linette, AS Bear , BM Carreno - Clinical Cancer Research, 2024 - AACRhttps://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-23-1212/733759 Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting AS Bear , T Blanchard, J Cesare , MJ Ford - Nature , 2021 - nature.comhttps://www.nature.com/articles/s41467-021-24562-2 Abstract PR08: TCR1020 specific for KRAS G12V restricted to HLA-A* 11: 01 exhibits potent and precise antigen specificity for clinical development AS Bear , RB Nadler, J Scholler, RH Vonderheide - Molecular Cancer , 2023 - AACRhttps://aacrjournals.org/mcr/article/21/5_Supplement/PR08/725803 Abstract PR04: Anti peptide-HLA (TCR-like) antibodies specific for the KRAS G12V neoantigen A Maserati, D Makris, B Kiefel, M Beasley - Molecular Cancer , 2020 - AACRhttps://aacrjournals.org/mcr/article-abstract/18/5_Supplement/PR04/233751

• Marque: Biosynth